OPRX logo

OptimizeRx Corporation Stock Price

NasdaqCM:OPRX Community·US$226.5m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 12 Fair Values set on narratives written by author

OPRX Share Price Performance

US$12.15
6.74 (124.58%)
US$24.33
Fair Value
US$12.15
6.74 (124.58%)
50.1% undervalued intrinsic discount
US$24.33
Fair Value
Price US$12.15
AnalystConsensusTarget US$24.33
AnalystHighTarget US$32.00
AnalystLowTarget US$17.00

OPRX Community Narratives

AnalystConsensusTarget·
Fair Value US$24.33 50.1% undervalued intrinsic discount

Pharmaceutical Digital Engagement Will Unlock Future Value

0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AnalystHighTarget·
Fair Value US$32 62.0% undervalued intrinsic discount

Digital Health Adoption And AI Will Drive Secular Expansion

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystLowTarget·
Fair Value US$17 28.5% undervalued intrinsic discount

Heightened Data Privacy And Provider Skepticism Will Hinder Healthcare Transformation

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$17
28.5% undervalued intrinsic discount
Revenue
8.82% p.a.
Profit Margin
9.18%
Future PE
31.89x
Price in 2029
US$21.65
US$32
62.0% undervalued intrinsic discount
Revenue
12.22% p.a.
Profit Margin
8.65%
Future PE
58.02x
Price in 2028
US$40.68

Trending Discussion

Updated Narratives

OPRX logo

OPRX: Higher Guidance And Margin Expansion Will Reshape Long Term Earnings Power

Fair Value: US$17 28.5% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
OPRX logo

OPRX Will Extend Double Digit Revenue Trajectory With New Multi Year Partnerships

Fair Value: US$32 62.0% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
OPRX logo

OPRX: Recurring Revenue Shift And 2026 Guidance Will Drive Future Upside

Fair Value: US$24.33 50.1% undervalued intrinsic discount
5 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Good value with adequate balance sheet.

0 Risks
3 Rewards

OptimizeRx Corporation Key Details

US$109.5m

Revenue

US$38.0m

Cost of Revenue

US$71.5m

Gross Profit

US$71.5m

Other Expenses

US$34.0k

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
0.0018
65.31%
0.031%
23.0%
View Full Analysis

About OPRX

Founded
2006
Employees
129
CEO
Stephen Silvestro
WebsiteView website
www.optimizerx.com

OptimizeRx Corporation operates as a digital healthcare technology company. The company offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers’ target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, HUB awareness, limited distribution drug information, and patient support program messaging through healthcare professionals; and media execution solutions, which deliver messages through consumer omnichannel network, including through programmatic display, programmatic connected television/over-the-top, programmatic social media, addressable television, digital out-of-home, programmatic audio, and email/direct mail. It also offers pharmacy alerts, which flag pharmacies that have prescription medications in stock; and financial messaging solutions, which provide prescribers visibility to branded copay offers for patients directly within electronic health record systems and ePrescribing platforms. The company was founded in 2006 and is based in Waltham, Massachusetts.

Recent OPRX News & Updates

Recent updates

No updates